About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 1057 record(s)
Req # A-2019-001594
Adverse Reaction Report (AER) for DEXILANT. Report numbers: E2B_02717363, E2B_02763747.Organization: Health Canada
March 2020
Req # A-2019-001402
Adverse Reaction Report (AER). Report numbers: E2B_01896360, E2B_00001827, 000450580, E2B_00269887, E2B_02157964, E2B_00844869, E2B_01378894, E2B_01122880, E2B_01280807, E2B_01164864, E2B_01164861.Organization: Health Canada
March 2020
Req # A-2019-001430
Adverse Reaction Report (AER). Report numbers: E2B_02535224, E2B_02066819.Organization: Health Canada
March 2020
Req # A-2019-001475
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-119737-837.Organization: Health Canada
March 2020
Req # A-2019-001484
Adverse Reaction Report (AER). Report numbers: E2B_02216112, 000717858, 000727615, E2B_00571140, E2B_00280120, 000685895, 000530577, E2B_01672103.Organization: Health Canada
March 2020
Req # A-2019-001501
Adverse Reaction Report (AER) for ONDANSETRON. Report numbers: E2B_02563606, E2B_02567480, E2B_02567680, E2B_02567753, E2B_02571395, E2B_02578682, E2B_02579659, E2B_02580616, E2B_02587235, E2B_02607214, E2B_02613380, E2B_02622326, E2B_02662711, E2B_02667571, E2B_02667599, E2B_02682778, E2B_02691505, E2B_02693082, E2B_02710210, E2B_02506534.Organization: Health Canada
March 2020
Req # A-2019-001531
Adverse Reaction Report (AER). Report numbers: 000633112, E2B_00926876, E2B_02189164.Organization: Health Canada
March 2020
Req # A-2019-001542
Adverse Reaction Report (AER). Report numbers: 000725020, E2B_00267242, 000516682, E2B_01318165, E2B_01318148, E2B_01318135, 000712654, 000516348, 000516685, 000612254, 000613636, E2B_01768498.Organization: Health Canada
March 2020
Req # A-2019-001568
Adverse Reaction Report (AER). Report numbers: E2B_01317931, E2B_02592729, 000720712, E2B_01390001.Organization: Health Canada
March 2020
Req # A-2019-001596
Adverse Reaction Report (AER) for ENTYVIO. Report numbers: 000729452, 000729545, E2B_02736316, E2B_02736386, E2B_02747272.Organization: Health Canada
March 2020